Upstate Active Clinical Trials

Study Title:

AACRU RC1126: A Randomized Phase II Trial of Erlotinib Alone or in Combination with Bevacizumab in Patients with Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

What is the purpose of the study?

This randomized phase II trial studies how well giving erlotinib (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood vessels and spread. It is not yet known whether erlotinib is more effective when given alone or with bevacizumab.

Upstate Institutional Review Board (IRB) Number:

607863

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

ClinicalTrials.Gov ID:

NCT01532089

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Linda L Spillett, CCRP
Phone: 315-464-8237
Email: spilletl@upstate.edu

Return to Previous Page || Search Again